毕得医药新管理层完成公开亮相 未来拟聚焦国际化战略

Group 1 - The core viewpoint of the articles is that Shanghai Bid Pharma Technology Co., Ltd. has undergone significant management changes in 2024, with a new management team focusing on internationalization and growth strategies [1][2][3] - The new management team is characterized by internal promotions and a younger demographic, with key members having long tenures at the company, ensuring familiarity with its culture and operations [2][3] - The company aims to enhance its global presence, having established regional centers in the US, India, and Germany, and is focusing on expanding its market share in Europe, India, and Japan [3][4] Group 2 - In 2024, Bid Pharma's overseas revenue reached 616 million yuan, accounting for 55.89% of total revenue, indicating a strong international market presence [3] - The company has implemented an equity incentive plan for 65 employees, with performance targets set for revenue and net profit growth of at least 10% in 2025 and 20% in 2026 [4] - The equity incentive plan is seen as a strategic tool to align the interests of key talents with the long-term development of the company, enhancing its governance structure [4]